Baillie Gifford & CO Denali Therapeutics Inc. Transaction History

Baillie Gifford & CO

$126 Billion
Q2 2024

A detailed history of Baillie Gifford & CO transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 13,763,596 shares of DNLI stock, worth $370 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares

13,763,596

Previous 14,041,228 1.98%

Holding current value

$370 Million

Previous $288 Million 10.92%

% of portfolio

0.25%

Previous 0.23%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	SELL	$14.96 - $23.22 $4.15 Million - $6.45 Million	-277,632 Reduced 1.98%	13,763,596 $320 Million
Q1 2024 May 01, 2024	SELL	$15.83 - $23.35 $3.47 Million - $5.13 Million	-219,496 Reduced 1.54%	14,041,228 $288 Million
Q4 2023 Jan 26, 2024	SELL	$16.2 - $23.18 $6.81 Million - $9.74 Million	-420,303 Reduced 2.86%	14,260,724 $306 Million
Q3 2023 Nov 13, 2023	SELL	$20.63 - $30.17 $3.36 Million - $4.91 Million	-162,743 Reduced 1.1%	14,681,027 $303 Million
Q2 2023 Jul 28, 2023	SELL	$23.37 - $32.96 $11.9 Million - $16.8 Million	-508,341 Reduced 3.31%	14,843,770 $438 Million
Q1 2023 May 03, 2023	BUY	$21.91 - $32.67 $5.1 Million - $7.6 Million	232,637 Added 1.54%	15,352,111 $354 Million
Q4 2022 Jan 24, 2023	BUY	$26.28 - $33.92 $10.6 Million - $13.7 Million	404,423 Added 2.75%	15,119,474 $420 Million
Q3 2022 Oct 27, 2022	SELL	$25.97 - $38.53 $4.01 Million - $5.95 Million	-154,323 Reduced 1.04%	14,715,051 $452 Million
Q2 2022 Aug 08, 2022	SELL	$20.88 - $35.19 $2.32 Million - $3.91 Million	-111,058 Reduced 0.74%	14,869,374 $438 Million
Q1 2022 May 05, 2022	SELL	$29.0 - $47.27 $2.2 Million - $3.59 Million	-75,949 Reduced 0.5%	14,980,432 $482 Million
Q4 2021 Jan 20, 2022	BUY	$42.59 - $55.02 $1.98 Million - $2.56 Million	46,565 Added 0.31%	15,056,381 $672 Million
Q3 2021 Oct 19, 2021	SELL	$48.48 - $78.23 $6.68 Million - $10.8 Million	-137,797 Reduced 0.91%	15,009,816 $757 Million
Q2 2021 Aug 02, 2021	BUY	$50.3 - $78.44 $108 Million - $169 Million	2,152,416 Added 16.56%	15,147,613 $1.19 Billion
Q1 2021 May 06, 2021	BUY	$53.8 - $81.53 $43.3 Million - $65.6 Million	804,941 Added 6.6%	12,995,197 $742 Million
Q4 2020 Feb 10, 2021	BUY	$36.89 - $93.56 $50.3 Million - $128 Million	1,363,078 Added 12.59%	12,190,256 $1.02 Billion
Q3 2020 Nov 12, 2020	BUY	$23.13 - $38.84 $35.8 Million - $60.1 Million	1,547,984 Added 16.68%	10,827,178 $388 Million
Q2 2020 Aug 12, 2020	BUY	$16.01 - $28.82 $2.39 Million - $4.31 Million	149,442 Added 1.64%	9,279,194 $224 Million
Q1 2020 May 08, 2020	BUY	$14.2 - $27.98 $21.9 Million - $43.1 Million	1,539,505 Added 20.28%	9,129,752 $160 Million
Q4 2019 Feb 10, 2020	BUY	$14.4 - $19.99 $3.27 Million - $4.53 Million	226,784 Added 3.08%	7,590,247 $132 Million
Q3 2019 Nov 07, 2019	SELL	$15.32 - $21.92 $670,495 - $959,350	-43,766 Reduced 0.59%	7,363,463 $113 Million
Q2 2019 Aug 08, 2019	BUY	$18.5 - $28.14 $21.2 Million - $32.2 Million	1,145,003 Added 18.28%	7,407,229 $154 Million
Q1 2019 May 01, 2019	BUY	$17.99 - $24.65 $620,690 - $850,474	34,502 Added 0.55%	6,262,226 $0
Q4 2018 Feb 14, 2019	BUY	$13.88 - $21.75 $10.3 Million - $16.1 Million	741,303 Added 13.51%	6,227,724 $129 Million
Q3 2018 Nov 13, 2018	BUY	$12.46 - $21.74 $1.77 Million - $3.08 Million	141,788 Added 2.65%	5,486,421 $119 Million
Q2 2018 Jul 17, 2018	BUY	$15.25 - $21.02 $2.31 Million - $3.19 Million	151,787 Added 2.92%	5,344,633 $81.5 Million
Q1 2018 May 10, 2018	BUY	$15.36 - $24.8 $4.16 Million - $6.72 Million	271,063 Added 5.51%	5,192,846 $102 Million
Q4 2017 Feb 13, 2018	BUY	$15.04 - $21.45 $74 Million - $106 Million	4,921,783	4,921,783 $77 Million

Others Institutions Holding DNLI

# of Institutions

216

Shares Held

115M

Call Options Held

127K

Put Options Held

38.3K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.6B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account

Baillie Gifford & CO Denali Therapeutics Inc. Transaction History